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Abstract – Objectives - The aim of this prospective cohort study was to investigate whether the association 
of periodontal status with schizophrenia treatment outcomes differs by patient’s age. Subjects and meth-
ods - The study was performed on the consecutive sample of 67 patients diagnosed with schizophrenia and 
discharged because achieving remission criteria. Papilla bleeding index (PBI) was measured at hospital dis-
charge. Positive and negative syndrome scale (PANSS) total score, positive, negative and general symptoms 
subscales’ scores were measured at hospital discharge, after three, and after six months. Results: - After 
the adjustment for potential confounders, baseline PBI was significantly unfavorably associated with PANSS 
total score, negative and general symptoms subscales scores in the patients younger than 45 three and six 
months after the hospital discharge, and with the positive symptoms sub-scale in patients younger than 
34. At youngest 10% of patients, a unit difference in baseline PBI resulted in the 8.12 (95% CI 2.78-13.47; 
p=0.004) points higher total PANSS score three months later. Our study showed that the younger patients 
with worse periodontal status are at higher risk for poorer schizophrenia treatment outcomes and faster 
worsening of remission. This study demonstrates the necessity of more rigorous and more frequent control 
of younger schizophrenia patients with worse periodontal status after hospital discharge to achieve overall 
improvement of the patients’ quality of life as well as the efficacy of psychiatric therapies aimed toward the 
primary mental disorder.
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Introduction
Many studies have shown the association 
between poor periodontal status and schizo-
phrenia [1-5] which may be influenced by dif-
ferent factors. First generation antipsychotics 
as well as anticonvulsants used as mood stabi-
lizers in the treatment of  schizophrenia, may 
cause a hypo-salivation by blocking the para-
sympathetic stimulation of  salivary glands and 
so increase the risk for oral illnesses [4, 6, 7]. 
Lithium may cause dry mouth, sialorrhoea, ul-
ceration of  the oral cavity and infections [8]. 
Almost all antidepressants may cause xerosto-
mia, and significant number of  them causes 
dysgeusia [7]. Tricyclic antidepressants and 
other drugs with anticholinergic or antiadren-
ergic effects may cause hypo-salivation and 
consequent candidiasis and other oral infec-
tions [8]. Majority of  anxiolytics and hypnot-
ics causes xerostomia as well [7]. In addition to 
medication used in schizophrenia treatment, 
prevalence of  heavy smoking is higher in the 
population of  patients diagnosed with schizo-
phrenia [9] and smoking has a strong negative 
effect on periodontitis [10, 11]. In patients 
with higher negative symptoms the motivation 
and persistence in maintaining a proper oral 
hygiene may be impaired [4]. Poorer periodon-
tal status and more advanced average stage 
of  a newly diagnosed periodontal disease in 
schizophrenia patients may partially be a con-
sequence of  the lower dental healthcare utiliza-
tion [12]. Patients diagnosed with schizophre-
nia may erroneously interpret the symptoms 
of  periodontal disease, may have a lower pain 
sensitivity caused by antipsychotic drugs and 
may have a suppressed gingival bleeding due 
to the excessive smoking. All of  these can 
make patients seek treatments from dental 
medicine professionals less often and less than 
necessary [13-15]. Moreover, tremor and other 
motor symptoms or antipsychotic drugs side-
effects in addition to orally specific ones, may 
affect the patients’ ability to maintain oral hy-
giene [16]. Schizophrenia patients die from the 
same causes as the general population [17-20], 
however their expected life-span is 15 to 20 
years shorter and their quality of  life severely 
impaired [21]. Poor periodontal status further 
deteriorates patients’ quality of  life. In addi-
tion, a growing body of  literature indicates 
there are possible effects of  the somatic ill-
ness on the efficacy of  treatment of  psychosis 
itself  [22-24]. Kalakonda et al. proposed the 
hypothetical model of  bidirectional associa-
tion between periodontal disease and schizo-
phrenia in which psychosis and its treatment 
determines the poor oral hygiene, xerosto-
mia and lower utilization of  dental healthcare, 
while periodontal disease causes elevation in 
interleukins and in that way indirectly modu-
lates the dopaminergic metabolism [5]. Conse-
quently, periodontal status may affect schizo-
phrenia treatment outcomes. The objective of  
our study was to investigate whether the as-
sociation of  periodontal/gingival status with 
schizophrenia treatment outcomes is moder-
ated by patients’ age. This is an especially im-
portant issue due to potential higher/lower 
efficacy of  schizophrenia treatment in certain 
age groups. Keeping in mind serious conse-
quences schizophrenia has on the health sys-
tem, caregivers and patients’ families, as well 
as overall poor quality of  life of  schizophrenia 
patients [25], this research can hopefully add 
to the control of  the effect physical comor-
bidities have on the outcomes of  psychiatric 
therapies thus making them more efficient.
Subjects and methods
Study design
We performed this single-center, prospec-
tive cohort study during 2018 at Psychiatric 
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Hospital ‘Sveti Ivan’, Zagreb, Croatia. The 
study protocol was approved by Ethics Com-
mittees of  Psychiatric Hospital ‘Sveti Ivan’ 
and School of  Dental Medicine, University 
of  Zagreb, Zagreb, Croatia. All participants 
verified their informed consent to the princi-
pal investigator who did the enrollment. The 
study complied with the World Medical As-
sociation Declaration of  Helsinki [26]. Zero 
time for the assembly of  the cohort was the 
date of  the hospital discharge because of  
achievement of  remission criteria. Remission 
criteria were defined according to The Remis-
sion in Schizophrenia Working Group [27]: 
sum of  eight Positive and negative syndrome 
scale (PANSS) items [28] lower than 21 and 
no result on any particular item >4. Eight 
items were: P1. Delusions, P2. Conceptual 
disorganization, P3. Hallucinatory behavior, 
N1. Blunted affect, N4. Social withdrawal, 
N6. Lack of  spontaneity, G5. Mannerisms/
posturing, G9. Unusual thought content. The 
follow up measurement was performed at 
third and sixth month after the enrollment. 
Study population
Targeted population was the patients of  
both genders, diagnosed with schizophrenia 
(ICD-10: F20), 30-65 years old, discharged 
from the psychiatric hospital because of  
achievement of  remission criteria, who had 
2-5 previous relapses of  schizophrenia, and 
recommended maintenance therapy with the 
2nd generation antipsychotics. Schizophrenia 
diagnosis was established according to the 
DSM 5 outlines [29] that two or more of  the 
following symptoms must be present for at 
least one-month time period: delusions, hal-
lucinations, disorganized speech (e.g. frequent 
derailment or incoherence), grossly disorga-
nized or catatonic behavior, negative symp-
toms (such as diminished emotional expres-
sion), and at least one of  the symptoms must 
be delusions, hallucinations or disorganized 
speech. Exclusion criteria was acute suicidality. 
We chose a consecutive sample of  patients by 
the order of  their hospital discharge.
Sample size
Data on the expected prevalence of  peri-
odontal disease in schizophrenic patients 
were obtained from the Morales-Chavez et 
al. study conducted in 2014 [2]. A sample size 
of  59 is required in order to determine, with 
statistical significance, the minimal, clinically 
relevant association of  periodontitis with the 
weakening of  remission defined as a partial 
coefficient of  determination of  R2=0.35, after 
the adjustment for ten potential confounders. 
The targeted statistical power was set at 80% 
and the level of  statistical significance at 0.05. 
With the expected maximum of  10% lost for 
follow-up, the initially required sample size 
was 66. The power analysis was calculated 
using PASS 14 Power Analysis and Sample 
Size Software (2015). NCSS, LLC. Kaysville, 
Utah, USA, ncss.com/software/pass.
Treatment outcomes
The primary outcome was the PANSS to-
tal score at three months follow up, adjusted 
for the baseline PANSS score at hospital dis-
charge. Secondary outcomes were positive, 
negative and general symptoms PANSS sub-
scales scores at third month follow up, adjust-
ed for their baseline values, and all PANSS 
scores at sixth month follow up.
Papilla bleeding index (PBI) measurement
The independent variable for analysis in 
this research was PBI. Bleeding was provoked 
by the periodontal probe withdrawing from 
the base to the tip of  the papilla with a slight 
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pressure, first in the distal and then in the me-
sial sulcus. After the whole quadrant was pros-
trate, after 20-30 seconds, the bleeding inten-
sity was estimated: 0. no bleeding, 1. only one 
blood point occurred after the stimulation, 2. 
there was a thin line of  blood or several bloody 
points at the gingival edge, 3. the interdental 
triangle is more or less filled with the blood 
soon after probing; 4. profuse bleeding imme-
diately after probing. The PBI was expressed 
as the sum of  the bleeding values divided by 
the number of  the examined papilla.
Pre-planned covariates
Pre-planned possible confounders whose 
effects we controlled by multivariable analy-
sis were: gender, education, having children, 
number of  household members, working sta-
tus, monthly income per household member 
in EUR, current smoking of  tobacco, body 
mass index (kg/m2), having a chronic physical 
comorbidity, number of  previous psychiatric 
hospitalizations, treatment with antipsychot-
ics mono or combination therapy, treatment 
with benzodiazepines, antidepressants, mood 
stabilizers.
Statistical analysis
The primary analysis was performed us-
ing a Johnson-Neyman technique as imple-
mented in the Andrew Hayes ‘Process’ macro 
release 2.16.2 [30, 31]. We used Hayes Model 
Figure 1. Analysis conceptual diagram; Andrew F. Hayes Model 1; conditional effect of  X (PBI) 
on Y (change in PANSS) = b1 + b3M (patients’ age); estimates are based on setting covariates to their 
sample means
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1 (Figure 1). Unstandardized linear regres-
sion coefficients were presented with their 
95% confidence intervals (CI). All coeffi-
cients were adjusted for all preplanned con-
founders. Statistical significances of  PBI and 
age interaction were not corrected for mul-
tiple testing because we interpreted only four 
analysis that were pre-planned and described 
in Statistical analysis plan. The significance 
of  the difference in PANSS total score and 
particular subscales scores from the baseline 
to sixth month, was calculated by Wilcoxon 
Signed Ranks Test. Level of  statistical signifi-
cance was set at a two-tailed p<0.05 with CI 
set at 95% level. The analysis was carried out 
using the NCSS 12 Statistical Software (2018) 
(NCSS, LLC. Kaysville, Utah, USA).
Results
We enrolled 67 patients diagnosed with 
schizophrenia (Table 1), treated with the 2nd 
generation antipsychotics (Table 2), and dis-
charged from the psychiatric hospital after 
achieving the first criteria for remission. The 




 man 37 (55.2)
 woman 30 (44.8)
Age (years), median (IQR) 47 (40-53)
Education
 primary or secondary 52 (77.6)
 university 15 (22.4)
Having children 19 (28.4)
Number of  household members
 single 10 (14.9)
 2 19 (28.4)
 3 27 (40.3)
 ≥ 4 11 (16.4)
Working status
 employed 20 (29.9)
 unemployed 24 (35.8)
 retired 23 (34.3)
Monthly income per household member (EUR), median (IQR) 269 (169-337)
Smoking 35 (52.2)
Body mass index (kg/m2), median (IQR) 27 (22-29)
Data are presented as number (percentage) of  participants if  not stated otherwise
Abbreviations: IQR = interquartile range
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Table 2. Participants clinical characteristics at hospital discharge (n=67)
Baseline
Having a chronic physical comorbidity 21 (31.3)
Previous psychiatric hospitalizations,median (IQR) 5 (3-6)
Treatment with antipsychotics*
 monotherapy 48 (71.6)
 combination 19 (28.4)
Particular antipsychotics†
 paliperidone 22 (32.8)
 risperidone 15 (22.4)
 aripiprazole 13 (19.4)
 quetiapine 12 (17.9)
 olanzapine 11 (16.4)
 other antipsychotics‡ 6 (9.0)
Benzodiazepines 29 (43.3)




 proton pump inhibitors or H2 antagonists 7 (10.4)
 other pharmacotherapy∫ 9 (13.4)
Papilla bleeding index, median (IQR) 1.3 (1.00-2.21)
Papilla bleeding index (PBI)
 no bleeding 10 (14.9)
 only one bleeding point 26 (38.8)
 several isolated bleeding points or
 small blood area 20 (29.9)
 interdental triangle filled with blood
 soon after probing 8 (11.9)
 profuse bleeding when probing, blood
 spreads towards the marginal gingiva 3 (4.5)
Data are presented as number (percentage) of  participants if  not stated otherwise
Abbreviations: IQR = interquartile range
* All patients were treated with antipsychotics
† The sum exceeds 100% because of  combination therapies
‡ Other antipsychotics: zuclopentixol, amisulpiride, ziprasidone, sulpiride
∫ Other pharmacotherapy included: beta blockers, diuretics, ACE inhibitors, statins, thyroid hormones, 
antidiabetics
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cohort median age was 47 years (interquar-
tile range 41 to 53); 30 (45%) of  participants 
were women (Table 1). During the three and 
six months follow-up after the hospital dis-
charge, total PANSS score as well as all three 
symptoms PANSS sub-scales’ scores were sig-
nificantly lowered, indicating the further im-
provement in treatment outcomes (Table 3). 
After the adjustment for all confounders the 
baseline PBI was significantly associated with 
the change of  PANSS total score after three 
months, in patients younger than 45 years 
what was 48% out of  all patients, and in the 
patients older than 61 what was 4% out of  all 
patients. In the younger patient group, high-
er baseline PBI increased the risk for high-
er, less favorable PANSS score. In youngest 
10% of  patients, a unit difference in baseline 
PBI resulted in the 8.12 (95% CI 2.78-13.47; 
p=0.004) points higher total PANSS score 
three months later (Table 4). In the second 
youngest group (~ 40 years of  age), a unit 
difference in baseline PBI resulted in 5.79 
(95% CI 1.69-9.89; p=0.007) points higher 
total PANSS score at the 3rd month follow 
up. In the patients older than 61, the higher 
baseline PBI significantly lowered the risk for 
higher PANSS. After the adjustment for all 
14 preplanned confounders, PBI was inde-
pendently and significantly associated with 
the change in negative and general symptoms 
PANSS sub-scales’ scores at third month fol-
low up in the patients younger than 40, and 
in positive symptoms sub-scale in the pa-
tients younger than 34 (Table 4). At the sixth 
month follow up the results were comparable 
but less pronounced and PBI was not a sig-
nificant predictor of  the positive symptoms 
PANSS sub-scale score (data not shown). 
In all these cases the association was posi-
tive (unfavorable) (Figure 2). The association 
of  baseline PBI and the general symptoms 
PANSS score was significant but reversed in 
the oldest age group (data not shown). In this 










PANSS total score 54 (47-64) 46 (40-53) 43 (39-53) -11 (7-15) -20% <0.001
Subscales
 positive symptoms 14 (11-16) 10 (8-11) 9 (8-11) -5 (4-6) -36% <0.001
 negative symptoms 14 (12-17) 13 (11-14) 12 (10-14) -2 (0.4-4) -14% 0.015
 general symptoms 26 (23-32) 23 (21-29) 23 (21-29) -4 (2-6) -15% <0.001
Data are presented as median (interquartile range)
Abbreviations: PANSS = Positive and Negative Syndrome Scale; Δ = absolute difference in medians 
after six months and at hospital discharge; 95% CI = Bonett-Price 95% confidence intervals; Δ% = 
relative difference in medians calculated as (median after-six-months subtracted from the baseline val-
ue) and divided by the baseline value; p = two-tails statistical significance of  the difference in medians 
calculated using Wilcoxon Signed Ranks test
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Table 4. Adjusted* changes of  PANSS score in three months after the hospital discharge at unit 






 Age percentile (years)
  10th (34 years) 8.12 (2.78-13.47) 0.004
  25th (39 years) 5.79 (1.69-9.89) 0.007
  Median (47 years) 2.52 (-0.32-5.36) 0.081
  75th (53 years) -0.75 (-3.63-2.13) 0.601
  90th (56 years) -2.16 (-5.49-1.18) 0.200
Positive symptoms scale
 Age percentile (years)
  10th (34 years) 1.83 (0.06-3.60 0.043
  25th (39 years) 1.32 (-0.04-2.67) 0.057
  Median (47 years) 0.59 (-1.06-1.51) 0.205
  75th (53 years) -0.14 (-1.06-0.79) 0.768
  90th (56 years) -0.45 (-1.52-0.62) 0.405
Negative symptoms scale
 Age percentile (years)
  10th (34 years) 1.94 (0.50-3.38) 0.009
  25th (39 years) 1.44 (0.34-2.54) 0.012
  Median (47 years) 0.74 (-0.02-1.50) 0.056
  75th (53 years) 0.04 (-0.73-0.80) 0.927
  90th (56 years) -0.27 (-1.16-0.63) 0.552
General symptoms scale
 Age percentile (years)
  10th (34 years) 4.12 (1.41-6.83) 0.004
  25th (39 years) 2.87 (0.79-4.96) 0.008
  Median (47 years) 1.13 (-0.32-2.57) 0.125
  75th (53 years) -0.62 (-2.09-0.85) 0.399
  90th (56 years) -1.37 (-3.08-0.33) 0.112
Data are presented as median (interquartile range). Abbreviations: PANSS = Positive and Negative 
Syndrome Scale; PBI = papilla bleeding index; 95% CI = 95% confidence intervals; p = two-tails 
statistical significance of  the effect of  PBI on PANSS score at particular patients’ age percentile. * 
Coefficient were adjusted for baseline PANSS score (total, positive, negative, general respectively), gen-
der, education, having children, number of  household members, working status, monthly income per 
household member in EUR, current smoking of  tobacco, body mass index (kg/m2), having a chronic 
physical comorbidity, number of  previous psychiatric hospitalizations, treatment with antipsychotics 
mono or combination therapy, treatment with benzodiazepines, antidepressants, mood stabilizers
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Figure 2. PANSS scores at three months after the hospital discharge by baseline papilla bleeding 
index (PBI) in different patients’ age percentiles, adjusted for baseline PANSS score (total, positive, 
negative, general respectively), gender, education, having children, number of  household members, 
working status, monthly income per household member in EUR, current smoking of  tobacco, body 
mass index (kg/m2), having a chronic physical comorbidity, number of  previous psychiatric hospi-
talizations, treatment with antipsychotics mono or combination therapy, treatment with benzodiaz-
epines, antidepressants, mood stabilizers (n=67)
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age group, higher baseline PBI was associated 
with a more favorable outcome as measured 
by PANSS general symptoms scale.
Discussion
This prospective cohort study revealed 
that in schizophrenia patients, the association 
of  PBI with the change in total PANSS score 
and in general symptoms subscale scores, 
was different in patients of  different age in-
dicating a correlation between periodontal/
gingival health status and risk for poorer 
schizophrenia treatment outcomes during 
remission. More specifically, schizophrenia 
patients younger than 45 with worse peri-
odontal status are at higher risk for poorer 
schizophrenia treatment outcomes and faster 
relapse (Table 4). 
Objectively assessed oral health in patients 
diagnosed with schizophrenia is associated 
with patients age [32]. One explanation may 
be that the pathogenesis of  schizophrenia 
is less associated with periodontal disease in 
older patients where, as it was described, peri-
odontal status and inflammation exist partial-
ly independently of  the psychosis. In younger 
patients, worse periodontal status may indi-
cate worse underlying psychotic pathological 
processes that we are not able to assess by the 
baseline PANSS and so-defined achievement 
of  criteria for remission. 
In patients with higher negative symptoms 
the motivation and persistence in maintaining 
a proper oral hygiene may be impaired [4]. In 
addition, poorer periodontal status and more 
advanced average stage of  a newly diagnosed 
periodontal disease in schizophrenia patients 
may partially be a consequence of  the lower 
dental healthcare utilization [12]. Patients di-
agnosed with schizophrenia may erroneously 
interpret the symptoms of  periodontal dis-
ease, may have a lower pain sensitivity caused 
by antipsychotic drugs and may have a sup-
pressed gingival bleeding due to the excessive 
smoking [14, 15]. All of  these can make pa-
tients seek treatments from dental medicine 
professionals less often and less than nec-
essary. Moreover, tremor and other motor 
symptoms or antipsychotic drugs side-effects 
in addition to orally specific ones, may affect 
the patients’ ability to maintain oral hygiene 
[16]. Regular dental exams are associated with 
better periodontal status and less oral health 
problems, which is not the case with regu-
lar visits to the general medicine practitioner 
[33]. Therefore there is a growing need to uti-
lize routine, systematic oral health monitor-
ing for psychiatric hospital inpatients [34]. 
There are some other limitations of  our 
study. First, we performed this study in the 
single center in a highly urbanized country 
capital and in a specialized psychiatric hos-
pital. Although we can only speculate about 
the extent and direction of  the difference 
between this institution and a small, region-
al psychiatric ward in the less affluential re-
gions with lower availability of  periodontal 
healthcare, this possible limitation should be 
taken into account. Second, we used PBI as 
an assessment of  periodontal/gingival status 
hoping that, if  our hypothesis was correct, 
PBI relative simplicity and minimal invasive-
ness may encourage the introduction of  peri-
odontal exams in routine psychiatric practice. 
However, one has to keep in mind that more 
comprehensive indicators of  periodontal sta-
tus are available, e.g. periodontal inflamed 
surface area [35] or Bleeding on Brushing in-
dex [36], whereas PBI values mainly indicate 
the superficial inflammation of  the gingiva. It 
is possible that internal validity of  our study 
was slightly lower because of  PBI limited us-
ability as an indicator of  periodontal status, 
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but on the other hand, the use of  PBI gives 
our study high translational value. This result 
could potentially lead to implementation of  
a quick and non-expensive method for as-
sessing periodontal status in schizophrenia 
patients and therefore indirectly lead to iden-
tification of  patients that are at higher risk of  
disease relapse. 
In conclusion, our study demonstrates the 
need for more rigorous and more frequent 
control of  younger patients with worse peri-
odontal status after hospital discharge not 
solely on the account of  periodontal disease 
affect the patients’ quality of  life, but also for 
the improvement of  efficacy of  psychiatric 
therapies aimed toward the primary mental 
disorder.
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Povezica narušenog periodontalnog zdravlja u mlađih bolesnika sa 
shizofrenijom s pogoršanjem simptoma tijekom remisije: prospektivno 
kohortno istraživanje  
Sažetak – Cilj ove prospektivne kohortne studije bio je istražiti postoji li razlika u povezanosti parodontnog 
statusa sa slabljenjem kvalitete remisije shizofrenije ovisno o dobi pacijenta. Ispitanici i metode: - Istraživanje 
je provedeno na susljednom uzorku od 67 pacijenata s dijagnosticiranom shizofrenijom koji su otpušteni iz 
bolnice radi ostvarenih kriterija remisije. Indeks krvareće papile (PBI, engl. papilla bleeding index) izmjeren 
je pri otpustu iz bolnice. Ispitanici su procijenjeni ljestvicom pozitivnih i negativnih simptoma (PANSS) pri 
otpustu iz bolnice, nakon tri i nakon šest mjeseci. Rezultati: - Nakon prilagodbe za potencijalne zbunjujuće 
varijable, indeks krvareće papile bio je značajno inverzno povezan s ukupnim PANSS rezultatom, te rezultatom 
subljestvica za negativne i generalne psihotične simptome kod pacijenata mlađih od 45 godina nakon tri i na-
kon šest mjeseci poslije otpusta iz bolnice, te s rezultatom subljestvice za pozitivne simptome kod pacijenata 
mlađih od 34 godine. Kod najmlađih 10% pacijenata, jedinična razlika u indeksu krvareće papile bila je za 8.12 
(95% CI 2.78-13.47; p=0.004) viša za ukupni PANSS rezultat tri mjeseca nakon otpusta iz bolnice. Zaključci:- 
Naše je istraživanje pokazalo da mlađi pacijenti s lošijim parodontnim statusom imaju povećan rizik za lošiju 
kvalitetu remisije shizofrenije, odnosno brže pogoršanje simptoma tijekom remisije. Ovo istraživanje ukazuje 
na potrebu za pojačanom i češćom kontrolom mlađih pacijenata sa shizofrenijom koji imaju lošiji parodontni 
status nakon otpusta iz bolnice kako bi poboljšali kvalitetu života pacijenta kao i pridonijeli učinkovitijoj tera-
piji primarnog mentalnog poremećaja.
Ključne riječi: krvareća papila, PANSS, shizofrenija, parodontni status
